In this study, we performed an immunostaining for AR and PTEN expression to determine whether the dysplastic changes mimicking a cancer-like lesion acquire an androgen independency (Figure 7) and to ensure that lost or inactivated tumour suppressor gene PTEN will promote the progression of prostate carcinogenesis (Figure 8). The gene discussed is PTEN; the disease is medical procedure.